Eli Lilly 2026년 6월 4일 Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026 - Stocktwits
Eli Lilly 2026년 6월 4일 Pharmalittle: We're reading about fewer pharma investments in Germany, growing U.S. layoffs, and more - statnews.com
Eli Lilly 2026년 6월 4일 Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership - Pharmaceutical Technology
Eli Lilly 2026년 6월 4일 Eli Lilly forms billion-dollar genetic kidney disease partnership with US biotech Ascidian Therapeutics - medwatch.com
Eli Lilly 2026년 6월 3일 Lilly, Boehringer to slash at least $1B each from planned investments in Germany - Fierce Pharma
Eli Lilly 2026년 6월 1일 Lilly locks in 5-program R&D pact with China’s Haisco worth up to $3B, but targets unclear - Fierce Biotech
Eli Lilly 2026년 5월 28일 Eli Lilly Stock Heads for Record Close. CVS Weight-Loss Drug Coverage Drives It Higher. - Barron's
Eli Lilly 2026년 5월 28일 CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo - Fierce Pharma
Eli Lilly 2026년 5월 26일 Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continues - Fierce Biotech
Eli Lilly 2026년 5월 26일 Lilly announces three acquisitions to build infectious disease portfolio | Eli Lilly and Company - investor.lilly.com
Eli Lilly 2026년 5월 25일 Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study - statnews.com
Eli Lilly 2026년 5월 25일 A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia - PR Newswire
Eli Lilly 2026년 5월 25일 Lilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitors - Fierce Biotech
Eli Lilly 2026년 5월 21일 Lilly’s triple-acting obesity drug hits goal in Phase 3 trial - BioPharma Dive